Compare Biocon Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SUN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SUN PHARMA BIOCON /
SUN PHARMA
 
P/E (TTM) x 27.4 22.1 124.1% View Chart
P/BV x 3.1 2.4 131.5% View Chart
Dividend Yield % 0.3 0.7 46.8%  

Financials

 BIOCON    SUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
SUN PHARMA
Mar-19
BIOCON /
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs707679 104.2%   
Low Rs554375 147.5%   
Sales per share (Unadj.) Rs91.9121.1 75.9%  
Earnings per share (Unadj.) Rs16.713.4 124.9%  
Cash flow per share (Unadj.) Rs24.220.7 116.9%  
Dividends per share (Unadj.) Rs1.002.75 36.4%  
Dividend yield (eoy) %0.20.5 30.4%  
Book value per share (Unadj.) Rs101.6172.6 58.9%  
Shares outstanding (eoy) m600.002,399.26 25.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.94.4 157.7%   
Avg P/E ratio x37.739.4 95.8%  
P/CF ratio (eoy) x26.125.5 102.4%  
Price / Book Value ratio x6.23.1 203.1%  
Dividend payout %6.020.6 29.1%   
Avg Mkt Cap Rs m378,3301,264,650 29.9%   
No. of employees `0006.117.5 35.0%   
Total wages/salary Rs m11,65359,671 19.5%   
Avg. sales/employee Rs Th8,994.316,608.1 54.2%   
Avg. wages/employee Rs Th1,900.73,409.6 55.7%   
Avg. net profit/employee Rs Th1,635.31,833.8 89.2%   
INCOME DATA
Net Sales Rs m55,144290,659 19.0%  
Other income Rs m1,44410,255 14.1%   
Total revenues Rs m56,588300,914 18.8%   
Gross profit Rs m15,88363,076 25.2%  
Depreciation Rs m4,47817,533 25.5%   
Interest Rs m7095,553 12.8%   
Profit before tax Rs m12,14050,246 24.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m2,1236,009 35.3%   
Profit after tax Rs m10,02632,093 31.2%  
Gross profit margin %28.821.7 132.7%  
Effective tax rate %17.512.0 146.2%   
Net profit margin %18.211.0 164.7%  
BALANCE SHEET DATA
Current assets Rs m48,228310,692 15.5%   
Current liabilities Rs m30,376173,396 17.5%   
Net working cap to sales %32.447.2 68.5%  
Current ratio x1.61.8 88.6%  
Inventory Days Days6899 69.0%  
Debtors Days Days86112 76.6%  
Net fixed assets Rs m64,130232,477 27.6%   
Share capital Rs m3,0002,399 125.0%   
"Free" reserves Rs m57,980411,691 14.1%   
Net worth Rs m60,980414,091 14.7%   
Long term debt Rs m15,76615,226 103.5%   
Total assets Rs m121,924646,938 18.8%  
Interest coverage x18.110.0 180.3%   
Debt to equity ratio x0.30 703.1%  
Sales to assets ratio x0.50.4 100.7%   
Return on assets %8.85.8 151.3%  
Return on equity %16.47.8 212.1%  
Return on capital %16.810.2 164.8%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50666,025 23.5%   
Fx outflow Rs m10,39938,610 26.9%   
Net fx Rs m5,10727,415 18.6%   
CASH FLOW
From Operations Rs m11,54621,965 52.6%  
From Investments Rs m-7,138-6,813 104.8%  
From Financial Activity Rs m-2,417-27,305 8.9%  
Net Cashflow Rs m2,103-8,442 -24.9%  

Share Holding

Indian Promoters % 40.4 63.7 63.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.1 163.7%  
FIIs % 10.7 23.0 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.3 239.8%  
Shareholders   109,995 133,026 82.7%  
Pledged promoter(s) holding % 0.0 0.5 7.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; IndusInd Bank and Tata Steel Top Gainers(12:30 pm)

Share markets in India are presently trading on a flat note. The BSE Sensex is trading up by 41 points, while the NSE Nifty is trading up by 16 points.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

CoronaVirus' Impact on Indian Markets - And One Stock With the Potential to Make Crores...(Profit Hunter)

Feb 7, 2020

Even as the experts come to grips with impact of Coronavirus contagion on Indian stocks and economy, here's a stock not just immune to macro threats, but with the potential to offer crores in the long term.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

A Megatrend to Help You Find the Best Stocks of the Next Decade(The 5 Minute Wrapup)

Feb 12, 2020

Recent events have put climate change into the spotlight. Here's how you should play this megatrend...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Feb 20, 2020 01:59 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS